BDR Pharma, one of India’s leading generic pharmaceutical, on Wednesday announced that it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company, for the manufacturing and distribution of Baricitinib for the treatment of Covid-19 in India.
Baricitinib received restricted emergency use approval, for use in combination with remdesivir, for treatment of suspected or laboratory confirmed Coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients 2 years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), the Pharmaceutical company said in a release here.
Lilly received permission for restricted emergency use from the Central Drugs Standard Control Organization, a division of the Ministry of Health.
This collaboration between BDR and Lilly will increase the availability of Baricitinib in India, enhancing local treatment choices and favourably impacting the lives of those fighting COVID-19 in India.
